Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m(2)/day as 4...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Albertini, Mark R., Hank, Jacquelyn A., Gadbaw, Brian, Kostlevy, Jordan, Haldeman, Jennifer, Schalch, Heidi, Gan, Jacek, Kim, KyungMann, Eickhoff, Jens, Gillies, Stephen D., Sondel, Paul M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer-Verlag 2012
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502633/
https://ncbi.nlm.nih.gov/pubmed/22678096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1286-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia